United Therapeutics Corp.

RSS Feed
United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.
  • TickerUTHR
  • ISINUS91307C1027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Equity
ACET , AMD ...
1d 1d / 8h / 33m 16 EN
Wedbush
Wedbush Research

Wedbush Morning Call - Apr 12 2021 6:40AM

Equity
ACOR , ATVI ...
5d 5d / 17h / 20m 12 EN
Wedbush
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Equity
ACET , AMD ...
6d 6d / 12h / 46m 16 EN
Wedbush
Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

Tyvaso PH-ILD Approval on Schedule, Launch Underway; PT to $276

Equity
Health Care
United Therapeutics Corp.
12d 05/04/2021 8 EN
Wedbush
Wedbush Research

Wedbush Morning Call - Apr 01 2021 6:58AM

Equity
ACOR , AMD ...
16d 01/04/2021 12 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.73
Chart
Health Care
ABMD , GOOG ...
351d 01/05/2020 18 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Technology
VNET , ACAD ...
1y 24/04/2020 42 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Personal & Household Goods
ATVI , AEM. ...
1y 23/04/2020 44 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Health Care
ACAD , AMD ...
1y 20/04/2020 30 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Automobiles & Parts
ADNT , AVAV ...
1y 20/02/2020 11 EN
BusinessWire

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against United Therapeutics Corporation - UTHR

NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of United Therapeutics Corporation (NASDAQ: UTHR) resulting from allegations that United Therapeutics may have issued materially misleading business information to the investing public. On February 21, 2018, United Therapeutics disclosed that its cost of product sales was above expectations due to an increase in the royalty rate United Therapeutics is required to pa...

Free
Corporate Voice
Health Care
United Therapeutics Corp.
3y 24/02/2018 1 EN
BusinessWire

Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NASDAQ:UTHR). The investigation focuses on whether the Company and/or its directors and officers breached their fiduciary duties. Request more information now by clicking here: www.faruqilaw.com/UTHR. There is no cost or obligation to you. Take Action If you currently own United Therapeutics...

Free
Corporate Voice
Health Care
United Therapeutics Corp.
3y 21/02/2018 1 EN
BusinessWire

UNITED THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NasdaqGS:UTHR). The investigation focuses on whether the Company and its executives violated federal securities laws. On July 27, 2017, the Company reported its second quarter 2017 financial results in which it revealed an accrual of $210 million relating to settlement negotiations with the U.S. Department of Justice (...

Free
Corporate Voice
Health Care
United Therapeutics Corp.
3y 31/07/2017 1 EN
BusinessWire

UTHR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of United Therapeutics Corporation

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong notifies investors of an investigation concerning whether United Therapeutics Corporation (“United Therapeutics”) (NASDAQ:UTHR) violated federal securities laws. Click here to learn about the case: http://docs.wongesq.com/UTHR-Info-Request-Form-1660. There is no cost or obligation to you. On July 27, 2017, United Therapeutics disclosed that it has set aside $210 million in connection to a possible settlement with the U.S. Department of Justice whether the co...

Free
Corporate Voice
Health Care
United Therapeutics Corp.
3y 28/07/2017 1 EN
BusinessWire

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of United Therapeutics Corporation

LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of United Therapeutics Corporation (“United Therapeutics” or the “Company”) (Nasdaq: UTHR). If you purchased or otherwise acquired United Therapeutics shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA ...

Free
Corporate Voice
Health Care
United Therapeutics Corp.
3y 28/07/2017 1 EN
Wedbush
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Equity
ACET , AMD ...
1d 1d / 8h / 33m 16 EN
Wedbush
Wedbush Research

Wedbush Morning Call - Apr 12 2021 6:40AM

Equity
ACOR , ATVI ...
5d 5d / 17h / 20m 12 EN
Wedbush
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Equity
ACET , AMD ...
6d 6d / 12h / 46m 16 EN
Wedbush
Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

Tyvaso PH-ILD Approval on Schedule, Launch Underway; PT to $276

Equity
Health Care
United Therapeutics Corp.
12d 05/04/2021 8 EN
Wedbush
Wedbush Research

Wedbush Morning Call - Apr 01 2021 6:58AM

Equity
ACOR , AMD ...
16d 01/04/2021 12 EN
TheScreener

UNITED THERAPEUTICS sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of UNITED THERAPEUTICS (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date February 26, 2021, the closing price was USD 167.18 and its potential was estimated at USD 188.45.

EUR 12.52
Quant
Health Care
United Therapeutics Corp.
49d 27/02/2021 6 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch